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Abstract
Epidermal growth factor receptor (EGFR) is overexpressed in a variety of epithelial tumors and is considered to be an
important therapeutic target. Although gene amplification is responsible for EGFR overexpression in certain human
malignancies including lung and head and neck cancers, additional molecular mechanisms are likely. Here, we report
a novel interaction of EGFR with an HECT-type ubiquitin ligase SMURF2, which can ubiquitinate, but stabilize EGFR
by protecting it from c-Cbl–mediated degradation. Conversely, small interfering RNA (siRNA)–mediated knockdown
of SMURF2 destabilized EGFR, induced an autophagic response and reduced the clonogenic survival of EGFR-
expressing cancer cell lines, with minimal effects on EGFR-negative cancer cells, normal fibroblasts, and normal
epithelial cells. UMSCC74B head and neck squamous cancer cells, which form aggressive tumors in nude mice, signifi-
cantly lost in vivo tumor-forming ability on siRNA-mediated SMURF2 knockdown. Gene expressionmicroarray data from
443 lung adenocarcinoma patients, and tissue microarray data from 67 such patients, showed a strong correlation of
expression between EGFR and SMURF2 at the messenger RNA and protein levels, respectively. Our findings suggest
that SMURF2-mediated protective ubiquitination of EGFRmay be responsible for EGFRoverexpression in certain tumors
and support targeting SMURF2-EGFR interaction as a novel therapeutic approach in treating EGFR-addicted tumors.
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Introduction
Epidermal growth factor receptor (EGFR) overexpression is a common
occurrence in human malignancies of epithelial origin including lung
and head and neck cancers and has been correlated with poor prognosis
[1–3], and small molecules directed at EGFR kinase activity have pro-
vided definite but limited success [4–6]. We have shown that therapies
causing EGFR degradation, as opposed to simple inhibition of its
kinase activity, are far more potent both in killing cancer cells and in
sensitizing tumor cells to chemotherapy than simply inhibiting EGFR
kinase activity [7–9]. We, therefore, hypothesized that, instead of sim-
ply inhibiting EGFR kinase function, degrading EGFR may improve
the clinical outcome of already-existing strategies to control tumor cell
growth. Thus, it is important to better understand the molecular regu-
lators involved in maintaining EGFR protein stability.
In many cases, protein stability of important oncogenes or tumor
suppressor genes is controlled by multiple ubiquitin ligases. For exam-
ple, the stability of the checkpoint regulator and oncogene, CDC25A,
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is maintained by at least two different ubiquitin ligases, SCFβ-TrCP and
APCCdh1 [10–12]. Similarly, in the case of insulin-like growth factor
receptor I (IGF-IR), Mdm2, Nedd4, and c-Cbl act as ubiquitin ligases
[13,14]. The RING-type ubiquitin ligase, Cbl, is the major ligase that
catalyzes EGFR ubiquitination [15]; however, because EGFR is an im-
portant regulator of various cellular functions, we hypothesized that there
may be multiple ubiquitin ligases responsible for controlling its stability.
One such promising ligase to investigate in this regard is the HECT-
type ubiquitin ligase, Smad ubiquitination regulatory factor 2 (SMURF2)
[16,17]. Like other HECT-type ubiquitin ligases, SMURF2 has the
ability to ubiquitinate and degrade some proteins, e.g., the TGF-β re-
ceptor I [18] and associated SMAD proteins [19,20], but also has a
unique ability to protect other substrates, e.g., spindle assembly check-
point protein, MAD2 [21] and NEDD9/HEF1 [22]. The ubiquitin
ligase activity of SMURF2 is dependent on the presence of a co-
factor, SMAD7, which helps to recruit the E2 enzyme, UbcH7 to
the HECT domain of SMURF2 [23]. It has been reported that Smad7
overexpression can accelerate the oncogenic Ras-mediated tumor pro-
gression in a mouse squamous cell carcinoma model not only by inhib-
iting TGF-β signaling but also by upregulating EGFR activity [24].
SMURF2 and EGFR are known to be overexpressed in various squa-
mous cell carcinomas including esophagus [25–27], and Smad7 over-
expression activates EGFR signaling [24]. We have also identified
probable SMURF2-interacting motifs in EGFR, and SMURF2 has
the unique ability either to protect or to degrade key cellular proteins.
Therefore, we hypothesized that EGFR may be a novel substrate for
SMURF2. Indeed, we found that SMURF2 is capable of directly bind-
ing to EGFR; that knocking down SMURF2 led to ligand-dependent
EGFR ubiquitination and degradation, induced autophagic response,
and reduced clonogenic cell survival; and that SMURF2 targeting af-
fected the tumor-forming ability of UMSCC74B cells in nude mice.
When we discovered that SMURF2 could have these EGFR-directed
effects in vitro and in vivo, we decided to evaluate whether the presence
of SMURF2 and EGFR was correlated in patient specimens.
Materials and Methods
Reagents
A monoclonal antibody against human SMURF2 has been de-
scribed previously [18]. Rabbit polyclonal SMURF2 antibody was
purchased from Upstate Biotechnology (Lake Placid, NY) and c-Cbl,
glyceraldehyde-3-phosphate dehydrogenase, AKT, phospho-AKT
(Ser473), STAT3, and phospho-STAT3 (Tyr705) antibodies were
purchased from Cell Signaling Technology (Danvers, MA). EGFR
(sc-03), TGF-β receptor I (sc-398), and ubiquitin (P4D1) antibodies
were acquired from Santa Cruz Biotechnology (Santa Cruz, CA).
Sepharose conjugated with FLAG (M2) antibody, protease inhibitor
cocktail, EGF, and glutathione agarose beads were obtained from
Sigma (St Louis, MO). Anti–chicken cytokeratin 8 antibody was pur-
chased from Novus Biologicals (Littleton, CO). Tetra-His antibody was
purchased from Qiagen (Chatsworth, CA). Alexa 488 antimouse IgG,
Alexa 488 antirabbit, Alexa 594 antirabbit, and Alexa 555 antichicken
IgG were purchased from Invitrogen (Carlsbad, CA). SMURF2 small
interferingRNA (siRNA) used in this study has been described previously
[21] and was purchased from Thermo Fisher Scientific (Lafayette, CO).
Cell Cultures
Chinese hamster ovarian (CHO), SW620, A549, Panc1, BxPC3,
MiaPaca2, NIH3T3, and Het1A cell lines were purchased from the
American Type Culture Collection (Manassas, VA). The human head
and neck squamous cell carcinoma (HNSCC) cell lines UMSCC1 and
UMSCC74B were kindly provided by Dr Thomas E. Carey (Univer-
sity of Michigan, Ann Arbor, MI). NCI-H1975 cell line was a gift
from Dr Jeffrey Engelman (Massachusetts General Hospital, Boston,
MA). Stably transfected HeLa-LC3B-GFP–expressing cells were main-
tained in puromycin selection medium. All cell lines were grown in
either RPMI 1640 or Dulbecco modified Eagle medium supple-
mented with 10% fetal calf serum (Sigma). CHO cells were transiently
transfected with the constructs using Lipofectamine (Invitrogen) ac-
cording to the instructions of the manufacturer. siRNA transfections
were performed using Lipofectamine RNAi-max (Invitrogen) following
the manufacturer’s protocol.
Immunofluorescence Microscopy
Immunostaining was performed as previously described [21]. In
brief, fixed cells were washed with PBS, permeabilized with 0.2%
Triton X-100 on ice for 5 minutes, and stained with primary anti-
bodies at 4°C for 16 hours. Washed slides were then incubated with
fluorescence-conjugated secondary antibodies at 4°C for 1 hour, stained
with DAPI (Invitrogen), and photographed using an Olympus DP70
camera fitted to an Olympus 1X-71 microscope (Olympus America,
Inc, Melville, NY). Images were captured at either ×20 or ×60 magni-
fications and processed in Adobe PhotoShop CS4 by removing the un-
sharp mask.
Protein Analyses
For immunoblot analysis or immunoprecipitation, cells were lysed
by sonication in lysis buffer as described previously [28]. Immuno-
precipitation of EGFR was performed as previously described [29],
and immunoprecipitation for FLAG-tagged SMURF2 was performed
using Affi-FLAG(M2) beads as previously described [30].
GST Pull-down Assay
GST-SMURF2 was purified from bacteria as previously described
[30], and 1 μg of fusion protein still attached to agarose beads was
equilibrated in 0.5× Superdex buffer (1× Superdex buffer: 25 mM
HEPES, pH 7.5, 12.5 mM MgCl2, 10 μM ZnSO4, 150 mM KCl,
20% glycerol, 0.1% Nonidet P-40, and 1 mM EDTA) for 30 minutes
at 4°C and then washed three times with 0.5× Superdex buffer. Beads
were then incubated with either about 200 or 600 ng of purified His-
tagged EGFR protein (Creative BioMart, New York, NY) was then
added to the washed beads and incubated overnight at 4°C. The
beads were washed three times using 0.5 Superdex buffer and boiled
in Laemmli buffer, and the bound SMURF2-EGFR complex was
immunodetected after immunoblot analysis with SMURF2 and Tetra-
His (for EGFR) antibodies.
Reverse Transcription–Polymerase Chain Reaction
Semiquantitative reverse transcription (RT)–polymerase chain re-
action (PCR) was performed as described previously [31]. In brief,
total RNA was isolated using Qiagen RNeasy mini kit (Qiagen, Inc,
Valencia, CA) from cells according to the manufacturer’s protocol.
Total RNA (1 μg) was subjected to RT reaction with the use of the
SuperScript first-strand synthesis system (Invitrogen). After the RT re-
action, RNase H was added to remove the RNA template from the
reaction mixture. Subsequently, PCR was performed in a total volume
of 25 μl with 1 μl of the RT product. The primers used for human
SMURF2 messenger RNA (mRNA) were 5′ tagccctggcagacctctta 3′
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and 5′ aatacacctggccttgttgc 3′ for amplification of a 218-bp product
and for human EGFR mRNA were 5′ cagcgctaccttgtcattca 3′ and 5′
tgcactcagagagctcagga 3′ for a 195-bp product. The primers used for
coamplification (238 bp) of the control glyceraldehyde-3-phosphate
dehydrogenase mRNA were 5′ gagtcaacggatttggtcgt 3′ and 5′ ttgattttg-
gagggatctcg 3′. The reaction was performed in an Eppendorf PCR
machine, at 94°C for 30 seconds, followed by 30 cycles of 94°C for
30 seconds, 54°C for 45 seconds, and 72°C for 1 minute. Amplified
DNAs were analyzed by agarose gel electrophoresis, and signals in
ethidium bromide–stained gels were quantified using the EDAS-290
imaging system (Kodak, Rochester, NY).
Clonogenic Cell Survival Assay
Clonogenic assays were performed using standard techniques [32].
The fraction surviving for each treatment was normalized to the sur-
vival of the control cells. The effects of SMURF2 siRNA-induced
clonogenic death were calculated by comparing the survival fraction
with that of the control siRNA-treated group.
In Vivo Tumor Growth Studies
Mice were handled according to the established procedures of the
University of Michigan’s Laboratory Animals Maintenance Manual.
UMSCC74B cells were either left untreated or treated with either
control or SMURF2 siRNA as previously described. To generate
tumor xenografts, 50,000 UMSCC74B cells from each of the three
subgroups (untreated, control siRNA treated, or SMURF2 siRNA
treated) were transplanted subcutaneously at four different locations
into athymic nude Foxn1nu mice (Harlan Laboratories, Indianapolis,
IN). For the untreated and control siRNA-treated groups, three ani-
mals were injected in each group, whereas in SMURF2 siRNA group,
we used four mice. Thus, in case of untreated and control siRNA-
treated groups, we have followed the tumor growth of 12 individual
tumors, whereas we followed 16 tumors in the SMURF2 siRNA-
treated group. Tumor latency was calculated based on the post-
injection day and when a palpable tumor was first detected. Animals
were killed when the largest tumor diameter reached to the protocol
approved size of 2 cm. The length and width of the tumors were
measured every other day, and the tumor volume was calculated
using the following equation: 0.5 × length × width2 [33]. Relative
tumor volume was calculated by normalizing to the tumor size when
first detected.
Tissue Microarray Immunofluorescence Staining and
Evaluation by Automated Quantitative Analysis
The lung adenocarcinoma tissue microarray (TMA) used in the
study was constructed as previously described [34]. The TMA slides
were deparaffinized in xylene and rehydrated using serial ethanol dilu-
tions, and antigen site unmasking was performed by immersing slides
in 100-nM citrate buffer for 20 minutes at high pressure and tem-
perature inside a pressure cooker. Slides were then washed in TBS,
blocked for 1 hour, and incubated in primary antibody at 4°C over-
night. Slides were then washed again in TBS, incubated in secondary
antibody for 1 hour at room temperature, rewashed, and prepared with
a coverglass after a drop of ProLong Gold antifade reagent with 4′,
6-diamidino-2-phenylindole (Molecular Probes, Eugene, OR)was added
to each sample. Fluorescence images were acquired using an Olympus
DP70 camera fitted in an Olympus 1X-71 microscope for representa-
tive pictures, and automated quantitative analysis (AQUA) was used
for automated image acquisition and analysis as previously described
[35], supported by University of Michigan Comprehensive Cancer
Center (UMSCC) tissue core.
Statistics
Pearson correlation was used to measure the degree of association
between two markers. Pearson correlation coefficient (r) was calculated,
together with the P value (null hypothesis is that r is in fact zero).
Results are presented as mean ± SEM of at least three experiments. A
significance level threshold of P < .05 was used.
Results
SMURF2 Directly Binds, Ubiquitinates, and Protects EGFR
from c-Cbl–Mediated Degradation
We began by examining if there were physical and molecular inter-
actions between EGFR and SMURF2. To investigate such interactions,
we used two different experimental systems: 1) CHO cells to over-
express EGFR and/or SMURF2 (because CHO does not express any
EGFR) and 2) UMSCC1 head and neck squamous cancer cell lines
that overexpress EGFR and SMURF2 and depend on EGFR for their
survival. To determine whether SMURF2 can interact with EGFR, we
performed immunoprecipitation using EGFR-specific antibodies from
cell lysates isolated from either CHO cells overexpressing EGFR and/
or SMURF2 or UMSCC1 cells. In both systems, we detected inter-
action between EGFR and SMURF2 (Figure 1A). Similarly, immuno-
precipitation studies using FLAG antibodies to pull down overexpressed
FLAG-tagged SMURF2 also detected EGFR-SMURF2 immuno-
complex (Figure 1B). Because immunoprecipitation under nondenatur-
ing condition does not rule out a direct or indirect interaction between
two proteins, we used a classic GST pull-down assay using bacterially
purified GST-SMURF2 and His-tagged EGFR purified from HEK-
293 cells. As shown in Figure 1C , we detected a direct physical inter-
action between EGFR and SMURF2.
To determine whether EGFR is ubiquitinated by SMURF2, we
overexpressed EGFR in CHO cells in the presence or absence of either
catalytically active wild-type (WT) or a catalytically dead C716A (CA)
mutant of SMURF2. EGFR was immunoprecipitated using specific
antibody, and immunoblot analysis was performed using antiubiquitin
antibody. As shown in Figure 1D (lower panel), WT SMURF2 signifi-
cantly increased the ubiquitination of EGFR, whereas SMURF2 (CA)
mutant had no effect, indicating that SMURF2 is an ubiquitin ligase
for EGFR. Interestingly, coexpression of EGFR andWT SMURF2 sig-
nificantly enhanced the steady-state level of EGFR, whereas SMURF2
(CA) mutant had minimal effects (Figure 1D, upper panel ). These
data indicate that SMURF2 can interact with EGFR leading to its
ubiquitination; however, unlike c-Cbl–mediated EGFR ubiquitina-
tion, SMURF2-dependent ubiquitination is protective for EGFR. Be-
cause of its autoubiquitinating ability, SMURF2 (CA) is more highly
expressed than SMURF2 (WT) [36]. We believe that the increased
presence of SMURF2 (CA) (Figure 1D) is responsible for a modest
alteration of EGFR steady-state levels, probably by counteracting
c-Cbl binding.
Next we addressed the question of why SMURF2 (WT) overexpres-
sion increased EGFR steady-state levels. One hypothesis was that
SMURF2-mediated ubiquitination may be counteracting Cbl’s effect
on EGFR, the only RING-type ubiquitin ligase reported to ubiquiti-
nate and downregulate EGFR. To test this hypothesis, we cotransfected
CHO cells with EGFR and c-Cbl either in the presence or in the
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absence of SMURF2 (WT) construct (Figure 1E ). We found that
SMURF2 overexpression abrogated c-Cbl–mediated ligand-induced
down-regulation of EGFR. Addition of excess EGF, which also
causes receptor internalization and degradation, was also significantly
inhibited by SMURF2 (WT) overexpression. These experiments
demonstrated a novel cooperative interaction between EGFR and
SMURF2, which may be important for oncogenic EGFR overexpres-
sion in human cancers.
siRNA-Mediated Knockdown of SMURF2 Decreased
EGFR Protein Levels with Enhanced Ubiquitination
and Leads to Reduced Clonogenic Survival of
EGFR-Dependent Cancer Cells
To better understand the physiological importance of the inter-
actions reported above, we performed siRNA-mediated acute knock-
down of SMURF2 in various tumor cell lines including lung (A549
and NCI-H1975), head and neck (UMSCC1, UMSCC74B), and
pancreatic (Panc-1) cells and also in immortalized normal esophageal
squamous epithelial cells (Het-1A). In all the cell lines tested, SMURF2
siRNA caused significant loss of endogenous EGFR protein levels
within 48 hours of siRNA transfection (Figure 2A). However, SMURF2
siRNA had no effects on EGFR mRNA levels as exemplified in
UMSCC1 cells (Figure 2B). To show the specificity of SMURF2
siRNA-mediated down-regulation of EGFR, the membrane was re-
probed with a TGF-β receptor I antibody, which remained essentially
unaltered wherever expressed (Figure 2A). These data indicate that
SMURF2 plays a critical and potentially selective role in maintaining
EGFR protein stability.
Because EGFR down-regulation affects the downstream survival
pathways, we examined the colony-forming efficiency of different cell
lines on SMURF2 siRNA and control siRNA treatments. For this
study, besides all these cell lines, we also used two additional pancreatic
cell lines (BxPC3 and Miapaca2), two EGFR-null cell lines (SW620
[colorectal] and CHO), and the normal mouse fibroblasts (NIH3T3).
Cells were either left untreated or transfected with either control
or SMURF2 siRNA as mentioned. At 24 hours after transfection,
cells were plated for clonogenic survival assays (Figure 2D). SMURF2
siRNA had minimal effects on clonogenic survival of EGFR-null
SW620 and CHO cells and also on normal epithelial cells (Het1A)
and fibroblasts (NIH3T3). However, all the EGFR-positive cancer
cells, irrespective of gefitinib resistance (T790M) mutation (NCI-
H1975), were sensitive to SMURF2 siRNA to varying extents. Among
them, UMSCC74B and NCI-H1975 cells were the two most affected
lines with approximately 98% reduction in clonogenic survival effi-
ciency (Figure 2D). These data indicate that SMURF2 siRNA had
a great effect on EGFR-dependent cancer cell survival than on nor-
mal cells, and thus SMURF2 knockdown might have therapeutic po-
tential. We have also looked at the EGFR downstream signaling
events, particularly, AKT and STAT3 phosphorylation, which also
showed significant down-regulation in SMURF2 siRNA-treated samples
(Figure W1).
SMURF2 siRNA Treatment Induced Autophagic Cell Death
in Cancer Cells
As loss of EGFR is known to induce autophagy [37], we wanted
to explore whether SMURF2 siRNA treatment was inducing an
Figure 1. SMURF2 interacts with, ubiquitinates and protects EGFR from c-Cbl–mediated down-regulation. (A) EGFR was immunopreci-
pitated (IP) from CHO cells cotransfected with EGFR and SMURF2 (left panel) or from UMSCC1 cells (right panel) and immunoblotted
(IB) with indicated antibodies. NRS indicates normal rabbit serum. MW marker indicated on the side. (B) Immunoprecipitation was per-
formed using Affi-FLAG Sepharose beads to pull-down FLAG-tagged SMURF2 from CHO cells cotransfected with EGFR and SMURF2,
and immunoblot analysis was performed using indicated antibodies. (C) GST-SMURF2 agarose beads were incubated with purified His-
tagged EGFR protein, and a GST pull-down assay was performed as described in Materials and Methods. Immunoblot analyses were
performed using indicated antibodies. (D) EGFR was either expressed alone or coexpressed either with WT or ligase dead (CA) mutant of
SMURF2 in CHO cells. Direct IBs as well as EGFR IP followed by Ub IB were performed on cell lysates 24 hours after transfection. (E)
EGFR was co expressed either with c-Cbl or SMURF2 in various combinations as indicated. Six hours after transfection, medium was
replaced with 10% FBS containing complete medium, and 24 hours after transfection, cells were either left untreated (−) or treated (+)
with 10 ng/ml EGF for 6 hours. Immunoblot analyses were performed using indicated antibodies.
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autophagic response, which may be responsible for reduction in clono-
genic cancer cell survival. Light chain 3 (LC3) is a well-established
marker for autophagy. During autophagy, the unmodified LC3-I
form is converted to the LC3-II form through lipidation, allowing
LC3-II to be associated with autophagosomes, appearing as punctu-
ate spots under microscope on immunostaining and running as a
faster migrating band by immunoblot analysis [38]. To test our
hypothesis, we have used HeLa cells stably expressing GFP-LC3,
a well-studied model for autophagy [39]. HeLa, an EGFR-positive
cell line, when treated with SMURF2 siRNA showed significant
reduction in the EGFR steady-state level compared with control
siRNA (Figure 3B). Like other EGFR-positive cancer cell lines (as
shown in Figure 2C), the clonogenic survival was significantly reduced
(0.95 ± 0.04 vs 0.49 ± 0.03) (Figure 3C) in SMURF2 siRNA-treated
HeLa–GFP-LC3 cells. Furthermore, SMURF2 siRNA-transfected
cells showed increased GFP-LC3 punctuate pattern 48 hours after
transfection (Figure 3A), and the same sample showed an increase
in the LC3-II form on immunoblot analysis (Figure 3B). These
data suggest that autophagy could be one of the mechanisms for
the loss of clonogenic survival in cancer cell lines on SMURF2
siRNA treatment.
Smurf2 Knockdown Abrogated Tumor-Forming Ability of
UMSCC74B Cells in Nude Mice
To explore the therapeutic potential of SMURF2 siRNA, we as-
sessed the in vivo effects of siRNA on UMSCC74B cancer cell line.
This cell line was chosen for two reasons: 1) according to our clono-
genic survival data (Figure 2C), SMURF2 siRNA had a robust effect
in this cell line; and 2) UMSCC74B cells form aggressive tumors in
nude mice within 4 weeks of subcutaneous injection. We found that
SMURF2 siRNA-treated UMSCC74B cells, rarely formed tumors
within the 75-day observation period, and those that did form had
a latency of more than 54 days (Figure 4). In contrast, nude mice car-
rying untreated UMSCC74B cells or cells pretreated with control
siRNA formed aggressive tumors with a median time-to-tumor de-
tection were more than 29 days and more than 26 days, respectively
(Figure 4). However, tumor growth rates were comparable between
the three groups once a palpable tumor was detected (Figure 4, upper
panel ). On the basis of the log-rank tests, there was significant difference
in time-to-tumor initiation between control siRNA and SMURF2
siRNA-treated groups (P = .001); however, there was no significant
difference on time-to-tumor initiation between control siRNA and un-
treated group (P = .17). The difference was marginally significant
between SMURF2 siRNA-treated and untreated groups (P = .09). From
these studies, we concluded that SMURF2 siRNA has therapeutic
potential, which may be mediated through EGFR down-regulation.
Correlation of Expression between EGFR and SMURF2
in Lung Adenocarcinoma Patients at the mRNA and
Protein Levels
To better understand the potential clinical importance of the inter-
action between EGFR and SMURF2, we analyzed gene expression
microarray data from 443 lung adenocarcinoma patients [34]. Among
all the different HECT family members, SMURF2, which belongs to
the Nedd4 subfamily, showed the strongest correlation of expression
(r = 0.42, n = 443, P < .001) with EGFR mRNA (Figure 5A and
Table 1). To determine the correlation between EGFR and SMURF2
expression at the protein level, we performed coimmunofluorescence
Figure 2. siRNA-mediated SMURF2 down-regulation decreased EGFR protein levels and clonogenic cancer cell survival. (A) Different can-
cer (lung [A549, NCI-H1975], head and neck [UMSCC1 and 74B], and pancreatic [Panc1]) and a normal epithelial cell line (Het1A) were
transfected either with 50 nM of control (C) or SMURF2 (S) siRNA. Cell lysates were prepared 48 hours after transfection, and immunoblot
analyses were performed using different antibodies as indicated. (B) Total RNAs were isolated from UMSCC1 cells treated with either C or
S siRNA and RT-PCR was performed as described previously [31]. (C) Different cancer (A549, NCI-H1975, UMSCC1, UMSCC74B, BxPC3,
MiaPaca2, Panc1, and SW620) and normal cell lines (Het1A, NIH3T3, and CHO) were transfected with siRNA (C or S). Twenty-four hours
after transfection, cells were trypsinized and replated to determine the clonogenic survival efficiency. Survival efficiency for untreated
group was normalized to 1 to determine the survival fraction for the control and SMURF2 siRNA group for each cell line and presented
as mean ± SEM from three independent experiments.
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staining on a TMA isolated from 67 lung adenocarcinoma patients.
We used cytokeratin 8 (CK8) as an epithelial cell marker to specify
tumor cells, which helped quantifying the tumor cell–specific EGFR
and SMURF2 protein levels. On the basis of the AQUA, EGFR and
SMURF2 showed a strong correlation (r = 0.711, n = 67, P < .0001) at
the protein level (Figure 5B). Representative fluorescence micrographs
of a patient’s lung tumor showing tumor-specific EGFR and SMURF2
colocalization along with CK8 staining is shown in Figure 5C . Inter-
estingly, based on the same gene expression microarray data, among
the various families of ubiquitin ligases (e.g., RING and HECT), EGFR
mRNA levels was most positively correlated with SMURF2 (data
not shown).
Discussion
In this study, we have identified EGFR as a novel substrate for
SMURF2, which ubiquitinates but stabilizes EGFR; conversely,
EGFR undergoes EGF-mediated rapid turnover in the absence of
SMURF2. Such observations have both basic as well as significant
clinical relevance: (a) it identifies a molecular regulator, which may
be critical in tumor cell–specific EGFR overexpression, a common
occurrence in a variety of epithelial tumors; and (b) it also identifies
SMURF2 as a novel therapeutic target, down-regulation of which can
degrade EGFR protein leading to reduced clonogenic survival of
EGFR-addicted cancer cells and inhibition of tumor initiation in a
xenograft model. A major advantage of this approach is that it does
not target receptor kinase activity, so that tumor response is indepen-
dent of potential drug-resistant EGFR (T790M) mutations. These
findings motivate a search for an agent that would disrupt EGFR-
SMURF2 binding, degrade EGFR, and cause cancer cell death.
Our study shows that EGFR joins a growing group of receptors
that can undergo ubiquitination by HECT-type ubiquitin ligases. In
this study, we have demonstrated a direct physical interaction between
EGFR and SMURF2, although the domain(s) involved in this inter-
action remains to be identified. Besides, it is interesting to study the
subcellular localization where EGFR-SMURF2 interaction is taking
place. Because SMURF2 localization is highly dynamic (nuclear as well
as cytosolic) and as previously reported SMURF2 interacts with TGF-β
receptor in distinct endosomal compartments [40], we hypothesize
that SMURF2 may be interacting mainly with the endocytosed EGFR
pool and thus plays a critical role in receptor recycling/degradation, an
area of research slightly underinvestigated.
Figure 4. siRNA-mediated SMURF2 down-regulation reduced tumor-forming potential of an HNSCC cell line in nude mice. Upper panel:
Relative tumor volume was calculated for each tumor by normalizing the first time detected tumor volume as 1. Tumor growth kinetics
was presented by plotting the relative tumor volume with respect to the days after injection. Lower panel: Total number of tumors
detected in each group and the median time-to-tumor detection in days.
Figure 3. SMURF2 knockdown induced autophagic response in
tumor cells. (A) HeLa-LC3-GFP cells were transfected with either
control or SMURF2 siRNA. Forty-eight hours after transfection, cells
were observed by fluorescence microscopy and photographed.
SMURF2 siRNA-treated cells showed increased punctate fluo-
rescence. Bar, 50 μm. (B) Protein lysates were isolated from the
samples and immunoblotted for indicated antibodies. Relative quan-
tification was performed using ImageJ software setting the control
siRNA value as 1. (C) HeLa cells were transfected with siRNA (C or
S). Twenty-four hours after transfection, cells were trypsinized and
replated to determine the clonogenic survival efficiency. Survival
efficiency for untreated group was normalized to 1 to determine
the survival fraction for the control and SMURF2 siRNA group and
presented as mean ± SEM from three independent experiments.
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We also found that SMURF2 can inhibit c-Cbl–mediated EGFR
down-regulation, but the molecular mechanism is not yet certain.
One plausible hypothesis is the differential ubiquitination pattern ex-
erted by the two different families of ubiquitin ligases. c-Cbl–mediated
ubiquitination of EGFR leads to its lysosomal degradation [41]. Be-
cause K63-linked polyubiquitin chain formation facilitates lysosomal
degradation of proteins [42,43] and c-Cbl was shown to catalyze
such ubiquitin linkages on EGFR [44,45], we are hypothesizing
that SMURF2 may be involved in attaching non–K63-linked poly-
ubiquitin chains, thereby counteracting c-Cbl activity. Furthermore,
different deubiquitinating enzymes [46,47] may be a critical in bal-
ancing the c-Cbl and SMURF2 activity, thus tightly regulate the
EGFR protein stability, alteration of which during oncogenesis leads
to EGFR overexpression. For future studies, the involvement of EGFR
in transcriptional/posttranscriptional regulation of SMURF2 also re-
mains an interesting question.
In conclusion, we have shown that EGFR is a novel substrate of
SMURF2, an interaction found to be critical for the receptor protein
stability in an ubiquitination-dependent manner. We also demonstrated
that the loss of SMURF2 caused rapid EGFR degradation irrespective
of the presence or absence of a drug-resistant mutation in EGFR and
decreased cancer cell survival and inhibition of tumor initiation in nude
mice. The presence of a strong correlation between the two oncogenes
in lung cancer patients suggested that our findings are clinically relevant.
These findings motivate the investigation of the therapeutic efficacy of
Table 1. Among All HECT Ubiquitin Ligases, SMURF2 Is Best Correlated with EGFR at the
mRNA Level in Lung Adenocarcinoma Patients.
HECT Ligases r* to EGFR
HERC family
HERC6 0.2841
HERC5 0.1207
HERC3 0.0664
HERC4 0.0311
HERC1 0.0102
HERC2 −0.0072
NEDD4 family
SMURF2 0.4186
SMURF1 0.2655
WWP2 0.2079
WWP1 0.0918
NEDD4 0.0585
ITCH −0.0514
NEDD4L −0.057
HECW1 −0.1091
Other HECTs
UBE3C 0.0559
KIAA0317 0.0543
HUWE1 0.0188
TRIP12 0.0047
UBE3B −0.1147
The Pearson correlation analysis was performed for 19 HECT ubiquitin ligases of three different sub-
families (HERC family, Nedd4 family, and other HECTs) to EGFR from gene expression data set of
lung adenocarcinoma patients as described previously [34] and tabulated. Among all the tested family
members, SMURF2 showed the best positive correlation (r = 0.42, n = 443, P < .001) to EGFR.
*Pearson correlation (n = 443, P < .001).
Figure 5. Significant correlation of expression between EGFR and SMURF2 in lung adenocarcinoma and H&N cancer patients. (A) Plots of
EGFR and SMURF2 matched expression from a gene expression microarray showing strong correlation (r = 0.42, n = 443, P < .001). (B)
TMAs obtained from lung adenocarcinoma patients were stained with SMURF2, EGFR, CK8, and DAPI. Immunofluorescence intensities
were quantified using AQUA for individual antibodies. To quantify tumor-specific EGFR and SMURF2 staining, CK8 staining was used as a
reference. Such analysis showed very strong correlation (r = 0.71, n = 67, P < .0001) between EGFR and SMURF2. (C) Representative
immunofluorescence pictures of TMA from lung and head and neck cancer patients stained with anti-EGFR, SMURF2, and CK8 antibodies.
Leftmost panels show the merged images of EGFR and SMURF2 staining showing colocalization (orange). Bars, 100 μm.
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SMURF2 knockdown in treating EGFR-addicted cancers more effec-
tively either as an individual therapy or in combination with already-
existing chemotherapy and/or radiotherapy.
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Figure W1. siRNA-mediated SMURF2 down-regulation decreased
EGFR protein levels, phosphorylation of AKT and STAT3, and clono-
genic cancer cell survival. A549 and UMSCC1 cell lines were trans-
fected either with 50 nM of control (C) or SMURF2 (S) siRNA. Cell
lysates were prepared 48 hours after transfection, and immunoblot
analyses were performed using different antibodies as indicated.
